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Background: There is insufficient evidence to determine whether acupuncture is a cost-effective treatment for
irritable bowel syndrome. The objective of this study is to assess the cost-effectiveness of acupuncture as an
adjunct to usual care versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).
Methods: Cost-utility analysis conducted alongside a pragmatic, multicentre, randomised controlled trial. 233
patients with irritable bowel syndrome were randomly allocated to either acupuncture plus usual care, or usual care
alone. Cost-effectiveness outcomes are expressed in terms of incremental cost per quality adjusted life year (QALY)
at one year after randomisation. Costs were estimated from the UK National Health Service perspective for a time
horizon of one year. Cost-utility ratios were estimated based on complete case analysis for the base case analysis,
where only patients with available EQ-5D and cost data were included. Sensitivity analyses comprised a multiple
imputation approach for missing data and a subgroup analysis for the more severe cases of IBS.
Results: The base case analysis showed acupuncture to be marginally more effective than usual care (gain of
0.0035 QALYs, 95% CI: -0.00395 to 0.0465) and more expensive (incremental cost of £218 per patient (95% CI: 55.87
to 492.87) resulting in an incremental cost-effectiveness ratio of approximately £62,500. Sensitivity analysis using
multiple imputation for missing data resulted in acupuncture appearing less effective and more costly than usual
care, so usual care is dominant. Subgroup analysis selecting the most severe cases of IBS (Symptom Severity Score
of over 300) suggested that acupuncture may be a cost-effective treatment option for this group, with a
cost-per-QALY of £6,500.
Conclusions: Acupuncture as an adjunct to usual care is not a cost-effective option for the whole IBS population;
however it may be cost-effective for those with more severe irritable bowel syndrome.
Trial registration: Current Controlled Trials ISRCTN08827905
Keywords: Acupuncture, Irritable bowel syndrome, Economic evaluation, Health technology assessment,
Quality of lifeBackground
Population-based studies have demonstrated that the
prevalence rates of irritable bowel syndrome range from
2.1% to 22% [1]. The main symptoms are abdominal
pain or discomfort, altered form, frequency and passage
of stools, and abdominal distension. IBS affects all age* Correspondence: eugena.stamuli@york.ac.uk
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reproduction in any medium, provided the orgroups and it is believed that factors such as familial
aggregation, early life events, diet and psychosocial con-
ditions might drive the development of the disease [1].
The disease is not life-threatening, but leads to signifi-
cant impairment of health related quality of life, which
reflects physical role limitations as well as pain and a
lower perception of general health [2]. As a conse-
quence, patients with IBS are more likely than those
without to have impaired daily routines, relationships,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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level of absenteeism and impairs workplace functioning;
the magnitude of impairment is directly related to sever-
ity and frequency of bowel symptoms [4].
In the UK, patients with gastrointestinal symptoms
are primarily seen by a GP. Of those diagnosed with
IBS, approximately 20% are referred to a gastroenter-
ologist or general physician and 9% to a surgeon [4].
Several studies have estimated the NHS costs associated
with IBS [3,5]. They have concluded that the direct and
indirect costs associated with IBS are substantial. The
cost driver is usually higher hospital inpatient episodes
experienced by patients with IBS. The loss due to
impaired productivity in the UK has also been esti-
mated to be significant [6] mainly due to missed days
of work which have been estimated to be between 1.53
[3] and 1.7 days per month [7].
A Cochrane review supports the finding that conven-
tional treatments for IBS are rarely effective in managing
all of the symptoms associated with IBS [8]. Hence, there
is a tendency of patients increasingly turning to comple-
mentary and alternative medicine [9], one of them being
acupuncture. There is insufficient evidence to determine
whether acupuncture is an effective treatment for IBS
[10], and no evidence of cost-effectiveness from an NHS
perspective. This paper reports the relative cost-
effectiveness of acupuncture for IBS, assessed as part of
a pragmatic randomized controlled trial undertaken in
the UK [11,12].
Methods
Study design, setting, participants and interventions
Details and clinical results of this trial are reported else-
where (clinical paper – under submission). Briefly, 233
participants were recruited from primary care in the
English NHS into a pragmatic randomised controlled trial
of acupuncture for IBS. 116 were randomised to receive a
short course of traditional acupuncture plus usual GP care
and 117 to receive usual GP care alone. The treatment
course of the acupuncture arm included up to 10 sessions
over a three month period [13].
The economic analysis assesses the relative cost-
effectiveness of adding acupuncture sessions to usual care
compared with usual care alone for the treatment of IBS.
A cost-utility analysis approach was adopted, where utility
data are based on the EQ-5D questionnaire collected at
three-monthly intervals from baseline to 12 months. The
UK NHS perspective was taken [14], where only costs
directly linked to the NHS budget were included. The
time frame of the analysis was one year; hence, no dis-
counting was applied to costs or outcomes.
The outcomes of the analysis are presented as incre-
mental costs per quality adjusted life year (QALY). Un-
certainty around the estimates is presented as theprobability that acupuncture added to usual care is cost-
effective for a range of values that decision makers are
willing to pay for gaining one additional QALY, illu-
strated using as cost-effectiveness acceptability curves
(CEACs).Resource use data and outcome measures
NHS costs (GP and nurse visits, emergency and elective
hospitalisations, outpatient attendances and contact with
other NHS professionals) were included. Resource use
data were collected from GP records. Data were col-
lected for 15 months, which included three months be-
fore randomisation and the one year follow-up period of
the trial. The prior period was used to assess the base-
line consumption of health care resources. All contacts
with health care professionals were recorded, not just
those relating to IBS, but where IBS was documented in
the patient notes this was recorded by the researcher.
This allows the estimation of cost-effectiveness based on
the disease specific resource consumption in addition to
the overall consumption during the trial period. In
addition, data were collected on the total number of
acupuncture sessions attended by each patient allocated
to the intervention arm.
For the outcome data, the EQ-5D instrument [15] was
used to measure and value patients’ health states. This
was collected at baseline (at the point of enrolment of
the participants in the trial) and at three, six, nine and
12 months post-randomisation. Patients completed the
EQ-5D instrument via a postal questionnaire. EQ-5D
captures health on five three-level domains: no problems,
moderate problems or severe problems in mobility,
self care, usual activities, pain-discomfort, and anxiety-
depression, resulting in 243 possible health states.
EQ-5D scores were converted to utility scores by using
the social tariff based on preferences of the UK general
population [16]. To calculate QALYs, the utility scores at
each of the five time points were plotted and the area
under the curve was estimated. This approach takes into
account both the utility score at each time point and the
duration of time between them, assuming that utility
changes are linear from one time point to the next.Unit costs
Unit costs were identified for four types of activities:
those provided in primary care (GP and practice nurse),
hospital based activity (outpatient clinics, emergency
and elective admissions), other NHS professionals (hos-
pital or community based) and acupuncture sessions. In-
formation on unit costs was extracted from three
sources: Unit costs of health and social care [17], NHS
reference costs [18] and NHS choices website [19]. Unit
costs (at 2010 prices) are illustrated in Table 1.
Table 1 Unit costs of health care services
Item [source] Unit Cost Notes
GP and practice nurse
GP [16] Per surgery consultation
lasting between 11.7 minutes
and 17.2 minutes
£44.5 Page 167
Average of £36 (short visit)
and £53 (long visit)
Nurse (GP practice) [16] Per consultation £12 Page 164
Hospital based activity (outpatient clinics, emergency and elective admissions)
Outpatient activity [17] Unit of activity £98 Outpatient Attendances Data
Elective admissions [17] Unit of activity £1612 Elective inpatient HRG
The unit cost was derived as a weighted
average of all the activities that had duration
of 1 day (similar to the duration of elective
admissions for IBS dataset)
Emergency admissions (for duration of stay
1 nights, 2 days) [17]
Event £134 Accident and Emergency Services: leading
to Admitted. The unit cost was derived as a
weighted average of all the activities.
Emergency admissions (for duration of stay
0 nights, 1 day) [17]
Event £103 Accident and Emergency Services: not Leading
to Admitted. The unit cost was derived as a
weighted average of all the activities.
Other NHS professionals (hospital or community based)
Physiotherapist Occupational therapist [16] Clinic visit £17 Page 151
Chiropodist/Podiatrist [16] Clinic visit £11 Page 154
Counsellor [16] Surgery consultation £71 Page 78
Community psychiatric nurse (CPN) [16] One hour of face-to-face contact £56 Page 160
Psychologist/Psychiatrist/
Psychotherapist [16]
One hour of client contact £81 Page 155. Assume psychiatrist and
psychotherapist as well
Mental health [16] Per hour of face-to-face contact £70 Page 184. Assume involvement of
community mental health team
Radiology/X-ray [17] Unit of activity £27 Outpatient Attendances Data
Diagnostic imaging
Ophthalmology/Eye care/Retinopathy [17] Unit of activity £80 Outpatient Attendances Data
Gynaecology/Colposcopy [17] Unit of activity £112 Outpatient Attendances Data
Family planning [17] Unit of activity £59 Outpatient Attendances Data for
Sexual and Reproductive Health Clinic
(previously referred to as Family Planning Clinic)
Midwife [17] Antenatal visit £46 Community Midwifery Services: Visits
Postnatal visit £58
Urology [17] Unit of activity £99 Outpatient Attendances Data
Medical Gastroenterology
Sigmoidoscopy/Colonoscopy [17]
Unit of activity £123 Outpatient Attendances Data
Neurology [17] Unit of activity £166 Outpatient Attendances Data
Acupuncture sessions
Initial session [18] Session £47.5 Initial sessions usually cost between £35 and
£60, and further sessions between £25 and £50.
Further session [18] Session £37.5 Unit costs calculated as average of two values
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EQ-5D scores and resource use data were missing for some
patients. The base case analysis was conducted as a
“complete case analysis” where only patients with available
utility scores at all points and available costs were included.
An additional analysis was conducted by including all
the patients that returned EQ-5D questionnaires for atleast one time-point and had at least partial information
on resource use. Missing EQ-5D scores were imputed
based on a group of variables (age, treatment allocation
and the utility scores of the patients at any time-point).
The cost data for the patients who had partial informa-
tion (e.g. they had left the GP surgery), were inflated
based on the time for which the information was
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the cumulative costs would increase proportionally for
the rest of the trial duration. For each of the scenarios,
two analyses were conducted; first by including all costs
irrespective of their nature, and second by including only
the IBS-related costs.
The differences in cost data are presented unadjusted
and adjusted for baseline costs; the latter being either
total or only IBS-related costs, depending on the nature
of the analysis. QALY data were adjusted for baseline
EQ-5D scores as recommended by Manca et al [20].
For the cost-effectiveness analysis, the mean differ-
ences in costs and effects were estimated by using seem-
ingly unrelated regressions and the 95% confidence
intervals around those were estimated using bias cor-
rected and accelerated (BCA) bootstrap methods. Ana-
lyses were conducted using STATA Version 10.1.
A pre-specified subgroup analysis was conducted based
on baseline Symptom Severity Scores (SSS) [21]. Patients
were grouped as mild (SSS = 75–175), moderate (SSS =
175-300) and severe (SSS =300+). Subgroup analysis was
conducted using only complete cases and only for the total
health care resource usage (not on the IBS-only costs).
Results
Missing data
Data were completely missing for 6 patients randomized
in the acupuncture and 20 in the usual care arm. Of
those, GP records could not be traced for 3 patients as
they had left the surgery and no further information was
available for them. 9 patients withdrew from the trial;
hence their GP records were not accessed. The records
of 14 patients were not available from the GP registry.
There was partial information on resource use for
three patients (two in acupuncture and one in the usual
care arm) as they left the GP surgery at some point after
the trial initiation. This was at 8 and 11 months after the
randomization date for two patients allocated in the acu-
puncture and one month after in the usual care arm.
There were missing utility scores for both arms of the
trial. The number of missing utility scores, due to either
missing questionnaires or missing domains in the EQ-5D
questionnaire, was higher for the usual care arm for all the
time-points. For the acupuncture, the range of missing
utility scores was 2.6% at baseline to 18.1% at month nine.
For the usual care arm, the rates of missing utility scores
ranged from 2.6% at baseline to 30.8% at month six.
Resource use
Table 2 presents levels of resource use based on the
available trial data. During the trial, participants in the
acupuncture arm had a higher mean number of GP vis-
its (6.7 vs. 5.9) and nurse visits (2.5 vs. 2) compared with
usual care. Usual care patients had a higher number ofemergency admissions but a lower number of outpatient
clinic contacts compared with the acupuncture arm.
Costs
A summary of costs based on the available trial data is
presented in Table 3.
Acupuncture patients had higher baseline costs com-
pared to the usual care patients (£144 vs. £123) as well
as during the trial (£600 vs. £574). The latter does not
include the cost of acupuncture sessions. IBS related
costs during the trial were also higher for the acupunc-
ture patients (£91 vs. £61), again without including the
cost of acupuncture sessions. Total costs during the trial
(acupuncture sessions plus health care costs) were
higher for the acupuncture group compared with usual
care patients (£940 vs. £574), a difference of £366.
Health states
Mean utility scores by time point are presented in
Table 4. The baseline scores were lower for the acupunc-
ture arm. At month 3, utility scores were higher for the
usual care patients compared to those receiving acu-
puncture (0.78 vs. 0.74, difference adjusted for baseline
scores of 0.0351) while at months 6 and 9 acupuncture
was marginally better or no different from the usual care
arm. At month 12, utility scores for the acupuncture
patients were marginally worse than those for the usual
care group. None of the differences reached conven-
tional levels of statistical significance.
Cost-effectiveness analysis
Base case analysis
The complete case analysis, based on all costs (IBS and
non IBS related) demonstrated that acupuncture results
in a QALY gain at 12 months of 0.0035 (BCA 95% CI:
-0.0395 to 0.0465) for unadjusted and 0.0033 (BCA 95%
CI: -0.0398 to 0.0462) adjusted for baseline costs (see
Table 5). Acupuncture is more expensive than usual care
resulting in incremental costs of £218.50 per patient
(BCA 95% CI: 55.87 to 492.87) for unadjusted and
£230.78 (BCA 95% CI:-34.52 to 496.08) for adjusted
results. This leads to an incremental cost-effectiveness
ratio of £62,429 (£69,933) per QALY gained based on
unadjusted (adjusted) estimates.
Figure 1 shows the incremental costs and QALYs.
Figure 2 presents the probability that acupuncture is
cost-effective for a range of maximum values that deci-
sion makers may be willing to pay for an additional
QALY gained. At a value of £30,000 per QALY gained,
often stated to be the borderline for the NHS [14],
acupuncture has a 40% probability of being cost effect-
ive. The analysis based on IBS-related costs only led
to similar conclusions i.e. acupuncture is associated
with higher costs and marginally better outcomes. The
Table 3 Mean costs based on available data
Type of costs Acupuncture (n = 110) Usual care (n = 97) Mean difference (95% CI)*
Mean(SD) (£ sterling) Mean(SD) (£ sterling)
Total baseline costs (for 3 months prior to trial) 144 (264) 123 (128) 21 (−38 to 79)
Total IBS baseline costs (for 3 months prior to trial) 20( 49) 21 (54) −1 (−15 to 13)
Health care costs during trial (excluding acupuncture) 600 (725) 574 (728) 26 (−174 to 225)
IBS-related costs during trial (excluding acupuncture) 91 (245) 61 (123) 30 (−24 to 84)
Acupuncture costs during trial 339 (98) 0 (0) 339 (321 to 356)
Total health care costs during trial (including acupuncture) 940 (740) 574 (728) 366 (164 to 567)
Total IBS-related costs during trial (including acupuncture) 431 (269) 61(122) 370 (311 to 429)
* Difference is not adjusted for baseline costs.
Table 2 Resource use
Acupuncture (n = 110) Usual care (n = 97) Mean difference (95%CI)
mean (SD) mean (SD)
GP visits
Baseline visits 1.67 (2.46) 1.65 (1.87) 0.02 (−0.58 to 0.63)
IBS related visits at baseline 0.22 (0.53) 0.36 (1.00) −0.14 (−0.36 to 0.07)
Visits during the trial 6.69 (8.69) 5.89 (5.74) 0.81 (−1.24 to 2.85)
IBS related visits during the trial 0.87 (1.83) 0.84 (1.62) 0.04 (−0.44 to 0.51)
Practice nurse
Baseline visits 0.42 (0.99) 0.46 (0.74) −0.05 (−0.29 to 0.20)
IBS related visits at baseline 0.05 (0.39) 0.02 (0.14) 0.03 ( −0.06 to 0.11)
Visits during the trial 2.48 (5.21) 1.99 (2.93) 0.49 (−0.69 to 1.67)
IBS related visits during the trial 0.12 (0.63) 0.05 (0.27) 0.07 (−0.07 to 0.20)
Elective hospitalisations
Baseline 0.01 (0.10) 0.00 (0.00) 0.01 (−0.01 to 0.03)
IBS related at baseline 0.00 (0.00) 0.00 (0.00) NA
During the trial 0.05 (0.21) 0.05 (0.22) 0.01 (−0.07 to 0.05)
IBS related during the trial 0.01 (0.10) 0.00 (0.00) 0.01 (−0.01 to 0.028)
Emergency hospitalisations
Baseline 0.04 (0.19) 0.09 (0.29) −0.06 (−0.12 to 0.01)
IBS related at baseline 0.01 (0.10) 0.00 (0.00) 0.01 (−0.01 to 0.03)
During the trial 0.25 (0.72) 0.32 (0.80) −0.07 (−0.28 to 0.13)
IBS related during the trial 0.03 (0.16) 0.00 (0.00) 0.03 (−0.01 to 0.06)
Outpatient clinics
Baseline 0.40 (1.00) 0.29 (0.66) 0.11 (−0.12 to 0.35)
IBS related at baseline 0.09 (0.35) 0.04 (0.20) 0.05 (−0.03 to 0.13)
During the trial 1.49 (2.30) 1.45 (2.45) 0.04 (−0.62 to 0.69)
IBS related during the trial 0.31 (0.98) 0.24 (0.83) 0.08 (−0.18 to 0.32)
Other NHS contacts
Baseline 0.07 (0.58) 0.06 (0.37) 0.01 (−0.12 to 0.13)
IBS related at baseline 0 (0) 0.01 (0.09) −0.01 ( −0.03 to 0.01)
During the trial 0.35 (1.10) 0.48 (2.13) −0.13 (−0.58 to 0.31)
IBS related during the trial 0.02 (0.18) 0 (0) 0.02 (−0.02 to 0.05)
Acupuncture sessions 9.18 (2.18) NA NA
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Table 4 Summary of utility scores based on EQ-5D at each time point (available cases)
Variable Acupuncture Usual care Adjusted mean difference (95% CI)*
Utility N Mean (SD) N Mean (SD)
Baseline 113 0.7121 (0.220) 114 0.7335 (0.1972) −0.0214(−0.0759 to 0.0332)
Month 3 106 0.7405 (0.219) 82 0.7810 (0.1614) −0.0351(−0.0833 to 0.0132)
Month 6 99 0.7528 (0.246) 81 0.7430 (0.2070) 0.0125(−0.0442 to 0.0692)
Month 9 95 0.7389 (0.229) 88 0.7379 (0.2234) 0.0008(−0.0546 to 0.0562)
Month 12 99 0.7342 (0.257) 90 0.7439 (0.2024) −0.0128(−0.0682 to 0.0425)
* The difference at 3, 6, 9, 12 moths is adjusted for baseline EQ-5D scores.
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both adjusted and unadjusted results.
Multiple imputation analysis
The analysis based on the multiple imputation of missing
outcome and cost data demonstrated that acupuncture is
less effective and more costly (including all IBS and non-
IBS related costs). Acupuncture costs £365.75 (BCA 95%
CI: 362.91 to 368.60) for unadjusted for baseline values
costs and £341.52 (BCA 95% CI: 339.00 to 344.03) for
the adjusted costs, more than usual care. The difference
in outcomes (acupuncture – usual care) is −0.0064 (BCA
95% CI: -0.0069 to −0.0059), leading to usual care being a
dominant option. The same conclusion is reached when
the analysis is based on only IBS-related costs.
Subgroup analysis
The subgroup analysis demonstrated that usual care is
dominant for mild and moderate cases of IBS patients, as








Total costs at baseline (full group) 113 (256) 126 (138)
Mild 72 (146) 169 (138)
Moderate 134 (329) 119 (126)
Severe 95 (122) 130 (170)
Total costs during trial (full group) 869 (680) 650 (833)
Mild 900 (936) 404 (264)
Moderate 876 (722) 698 (1014)
Severe 774 (403) 576 (355)
Outcomes
QALYs (full group) 0.7534 (0.1846) 0.7365 (0.1870)
Mild 0.7650 (0.2431) 0.8356 (0.1034)
Moderate 0.7822 (0.1720) 0.7752 (0.1541)
Severe 0.7049 (0.1885) 0.6683 (0.2363)
Note: baseline SSS missing for 1 Acupuncture patient and 3 Usual care patients.
#The difference in QALYs is always adjusted for baseline EQ-5D scores.
*The difference in costs is adjusted for baseline costs.usual care. For severe cases of IBS (with an SSS symptom
score of over 300), acupuncture appears more effective, al-
though also more costly. The QALY gain is approximately
0.031 (−0.0588 to 0.1206) and incremental costs are be-
tween £198 and £232 (−34.52 to 496.08) (unadjusted and
adjusted results). These lead to an incremental cost-
effectiveness ratio of £6,377 (£7,504) based on unadjusted
(adjusted) results. The probability that acupuncture is
cost-effective is slightly over 60% for willingness-to-pay
values of £20,000 to £30,000 per QALY gained. This
reflects the uncertainty around this result.Discussion
Principal findings
Our base case analysis demonstrated that acupuncture is
more costly and marginally more beneficial than the
usual care alone. Incremental cost effectiveness ratios
were within a range of £60,000 to £70,000 per QALY.
Sensitivity analysis resulted in usual care being domin-





218.50 (−55.17 to 492.18) 230.78 (−34.52 to 496.08)
496.46 (−244.24 to 1237.17 590.57 (−51.58 to 1232.72)
178.61 (−251.54 to 608.77) 164.59 (−229.41 to 558.60)
197.68 (−29.68 to 425.03) 231.87 (−11.68 to 475.42)
0.0035 (−0.0389 to 0.0458)# 0.0033 ( −0.0398 to 0.0462)
−0.0406 (−0.2038 to 0.1227) −0.0399 (−0.2053 to 0.1256)
−0.0103 (−0.0586 to 0.0380) −0.0107 (−0.0596 to 0.0382)
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Figure 1 Scatter plot of differences in costs and QALYs (complete case analysis- all costs included).
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for the patients with more severe IBS, as defined by the
IBS SSS score.Strengths and limitations
This study is the first economic evaluation of acupunc-
ture for IBS patients based on a randomized controlled












































Figure 2 Cost-effectiveness acceptability curve (complete case analysexternal validity and applicability to everyday clinical
practice in the UK setting.
Missing data limits slightly the validity of the results.
However, the analysis was based on two different scenar-
ios of handling missing data to test the robustness of the
conclusions. The sensitivity analysis did reverse the dir-
ection of difference in outcomes, making the case that
acupuncture is not a cost-effective option to be adopted
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the exclusion of medication costs in the economic ana-
lysis. As data on health resources consumption was
extracted from the GP records, tracking down the medi-
cation usage was problematic. However, previous re-
search has shown that the cost drivers are usually high
inpatient episodes and consultations with the GP [3,5];
hence, the exclusion of medication costs is very unlikely
to have changed the conclusions of this study.
Subgroup analysis, suggesting the possibility of acu-
puncture being cost-effective in more severe IBS patients,
is informative but preliminary. The uncertainty around
this result reflects the low sample size. There is a 60 per
cent probability that treatment of this subgroup would
meet NICE thresholds for cost-effectiveness.
Implications for clinical practice
The lack of notable benefit in terms of health utility from
the treatment drives the main conclusions of this ana-
lysis. This trial does not support the use of acupuncture
for IBS patients as an appropriate use of NHS resources.
It is possible that acupuncture may be a cost-effective
treatment option for patients with severe IBS, a group
that is difficult to treat, with poor quality of life [22,23].
Recommendations for future research
The subgroup analysis suggested that acupuncture may
be cost-effective for patients with severe IBS. This find-
ing can assist in hypothesis building for further examin-
ation and analysis. For example, a trial which is powered
to detect differences in outcomes for this subgroup of
patients might be pertinent.
In addition, an economic model to extrapolate long term
costs and effects would also be helpful in more clearly dem-
onstrating the cost effectiveness or otherwise of acupunc-
ture for this group of severe IBS patients, since the
utilisation of health care resources over the long term could
then be incorporated directly into the economic modelling
approach and accounted for in the economic analysis.
Conclusions
Our principal finding is that acupuncture as an adjunct to
usual care is not a cost-effective option for the whole IBS
population. Preliminary analysis suggests that it it may be
a cost-effective option for those with more severe irritable
bowel syndrome.
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